ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 3066
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

About the episode

Principle investigator of YELLOW III, Dr Annapoorna Subhash Kini (Mount Sinai Hospital, US) joins us to talk about the study that assessed the effect of evolocumab (Repatha) on coronary plaque morphology using intravascular imaging and gene expression analysis of peripheral blood mononuclear cells (PBMC) in 140 patients with stable CAD on maximally tolerated statin therapy (NCT01837823). 

The study showed that more intensive lipid lowering with addition of evolocumab for 26 weeks resulted in significant and substantial increase in the minimum FCT by OCT, reduction in NIRS maxLCBI4mm and reduction in atheroma volume by IVUS in angiographically non-obstructive lesions.

Questions:
1. What prompted the YELLOW studies? 
2. What are the baseline characteristics of the enrolled patients?
3. What are the key findings presented at ACC?
4. What are the potential implications for patient care?
 

Recorded on-site at ACC.23, New Orleans. 

Faculty Biographies

Annapoorna  Kini

Annapoorna Kini

The Mount Sinai Hospital

Annapoorna Kini, is an endowed Zena and Michael A Wiener Professor of Medicine, Director of Cardiac Catheterization Laboratory at The Mount Sinai Medical Center, Program Director of Interventional Cardiology Fellowship and Director of Structural Heart Intervention Program. Annapoorna is an international leader in the field of percutaneous coronary intervention and heart valve therapy.

Annapoorna is internationally acclaimed for her special expertise in performing complex and high-risk interventional cases, especially in chronic total occlusion, calcific and bifurcation lesions. She has extensive experience with the techniques of mitral, aortic balloon valvuloplasty, and septal (alcohol) ablation for the treatment of obstructive hypertrophic cardiomyopathy. She has been among the first interventional cardiologists in the country to use transcutaneous aortic valve implantation procedure in the treatment of patients with aortic stenosis and performs MitralClip…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.